When was Excision founded?

Excision was founded in 2015 and raised its 1st funding round 2 years after it was founded.

Where is Excision located?

Excision is headquartered in Philadelphia, United States.

How many employees does Excision have?

As of Jun 30, 2026, the latest employee count at Excision is 25.

Is Excision a funded company?

Excision is a funded company, having raised a total of $70.7M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Sep 06, 2017.

When was the latest funding round of Excision?

Excision's latest funding was a $***** Series A round on Feb 17, 2021, with participation from 9 investors. Its primary sector is Infectious Diseases. In United States, the Infectious Diseases sector has seen $699M in funding in 2026 to date.

Where does Excision rank among its competitors?

Excision ranks 20th amongst 293 active competitors, of which 76 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Leyden Labs, which secured $45.5M in Jun, 2026.

Who are the top competitors of Excision?

Excision's top competitors include HOOKIPA Pharma, Vaxart and Atea. Among them, Leyden Labs secured the most recent funding round in June, 2026.

Excision - 2026 Company Profile, Team, Funding & Competitors

Company Details

Excision BioTherapeutics, Inc., is a biotechnology company developing CRISPR-based therapies to cure viral infectious diseases. Excision is focused on improving the lives of chronically ill patients by eliminating viral genomes from infected individuals. By using CRISPR in unique ways, the Company has already demonstrated the first functional cure for HIV in animals. Excision is developing technologies and IP developed at Temple University and U.C. Berkeley. Excision is located in San Francisco, California and is supported by ARTIS Ventures, GreatPoint Ventures, Norwest Venture Partners, Adjuvant Capital, Cota Capital, WRVI Capital, IndusAge Partners, Loreda Holdings, Olive Tree, Anzu Partners, SilverRidge Venture Partners, Oakhouse Ventures, and Gaingels.

Website: excision.bio
Social
Email ID: *****@excisionbio.com

Key Metrics

Founded Year

2015

Location

Philadelphia, United States

Stage

Series A

Total Funding

$70.7M in 3 rounds

Latest Funding Round

Series A, Feb 17, 2021, $*****

Investors

GreatPoint Ventures & 18 more

Ranked

20^th among 293 active competitors

Employee Count

25 as on Jun 30, 2026

Similar Companies

HOOKIPA Pharma & 358 more

View Excision's full profile

Excision has raised a total funding of $70.7M over 3 rounds. Its first funding round was on Sep 06, 2017. Its latest funding round was a Series A round on Feb 17, 2021 for $*****. 9 investors participated in its latest round. Excision has 19 institutional investors.

Here is the list of recent funding rounds of Excision:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 17, 2021	6155043	Series A	2105089	2020468	5046618	3919774
Jun 01, 2019	6538303	Grant (prize money)	9442851	4639565	5888742	HHS
Sep 06, 2017	4654532	Seed	8101966	3288598	Artis Ventures	1138844

Access funding benchmarks and valuations. Sign up today!

View details of Excision's funding rounds and investors

Excision's employee count trend

Excision has 25 employees as of Jun 26. Here is Excision's employee count trend over the years:

Uncover Excision's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Excision include HOOKIPA Pharma, Vaxart and Atea. Here is the list of Top 10 competitors of Excision, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	HOOKIPA Pharma 2011, Vienna (Austria), Public	Developer of immunotherapies for the treatment of infectious diseases and cancer	$134M	Sofinnova Partners, Forbion & 12 others	70/100
2nd	Vaxart 2004, San Francisco (United States), Public	Developer of therapeutic solutions for treating multiple infectious diseases	$58M	Quantum Technology Partners, Life Science Angels ... & 8 others	67/100
3rd	Atea 2014, Boston (United States), Public	Developer of therapeutics for viral diseases	$293M	GSA Capital Partners, Bain Capital & 18 others	67/100
4th	Brii Biosciences 2018, San Francisco (United States), Public	Developer of biologics to treat hepatitis B infection	$415M	HongShan, Yunfeng Capital & 7 others	63/100
5th	Leyden Labs 2020, Leiden (Netherlands), Series B	Developer of nasal sprays containing antibodies targeting respiratory viruses in the nasal mucosa	$303M	Google Ventures, Clavystbio & 14 others	63/100
6th	eradivir 2020, West Lafayette (United States), Series A	Developer of immunotherapies for the treatment of infectious diseases	$20.4M	Research Bridge Partners, National Science Foundation ... & 2 others	62/100
7th	Memo Therapeutics 2012, Schlieren (Switzerland), Acquired	Developer of antibodies for treating infectious diseases and cancer	$97.2M	Swisscanto, Verve Ventures & 17 others	61/100
8th	VBI Vaccines 2001, Cambridge (United States), Public	Developer of vaccines for the treatment of infectious diseases	$65.1M	RTW Investments, Perceptive Advisors & 7 others	60/100
9th	Ascletis 2011, Hangzhou (China), Series B	Developer of small molecules for the treatment of multiple diseases	$255M	CBC Group, Goldman Sachs & 5 others	60/100
10th	Ocugen 2013, Aurora (United States), Public	Developer of therapeutic solutions to treat various eye disorders	-	Checkmate Capital, Colorado Office of Economic Development and International Trade ... & 5 others	59/100
20th	Excision 2015, Philadelphia (United States), Series A	Developer of CRISPR-based therapies to cure viral infectious diseases	$70.7M	Celesta Capital, Norwest & 17 others	55/100